| 787 |
Centers for Disease Control and Prevention |
Html |
en |
U.S. Flu Season Is Here, CDC Urges Vaccination |
U.S. Flu Season Is Here, CDC Urges Vaccination - CDC |
| health care provider | 0.654215 |
| influenza antiviral drugs | 0.640603 |
| Significant increases | 0.375867 |
| flu activity | 0.840048 |
| CDC Seasonal Influenza | 0.661952 |
| Regional percentages | 0.375565 |
| pregnant women | 0.499127 |
| flu vaccination | 0.561205 |
| health care providers | 0.491436 |
| baseline level | 0.37019 |
| widespread flu activity | 0.80986 |
| influenza activity | 0.564632 |
| new influenza-associated deaths | 0.478743 |
| chronic medical conditions | 0.734119 |
| influenza pandemic | 0.540956 |
| ILI increase | 0.452377 |
| flu illness | 0.558179 |
| H1N1 viruses | 0.404386 |
| seasonal flu viruses | 0.753021 |
| high risk | 0.448312 |
| influenza | 0.993181 |
| severe flu outcomes | 0.678337 |
| flu symptoms | 0.544474 |
| hospitalization rate | 0.461793 |
|
| flu virus type | 0.687263 |
| United States | 0.529647 |
| severe influenza infection | 0.641502 |
| flu vaccine | 0.751042 |
| respiratory viruses | 0.410511 |
| flu complications | 0.562213 |
| flu-related hospitalizations | 0.406621 |
| pH1N1 virus infection | 0.4635 |
| flu-related complications | 0.363286 |
| high ILI activity | 0.615417 |
| influenza surveillance report | 0.72411 |
| good sign | 0.363765 |
| pH1N1 virus | 0.47759 |
| laboratory-confirmed influenza | 0.576827 |
| 50 states | 0.380131 |
| influenza season | 0.547962 |
| regional activity | 0.39263 |
| flu-like symptoms | 0.37331 |
| 2013-2014 season | 0.366212 |
| people | 0.381699 |
| flu | 0.971915 |
| influenza complications | 0.503866 |
| influenza viruses | 0.680588 |
| flu season | 0.760865 |
|
CLICK HERE |
| 1066 |
Centers for Disease Control and Prevention |
Html |
en |
Concerns Regarding a New Culture Method for Borreliaburgdorferi Not Approved for the Diagnosis of Lyme Disease |
Christina Nelson, MD1, Sally Hojvat, PhD2, Barbara Johnson, PhD1, Jeannine Petersen, PhD1, Marty Schriefer, PhD1, C. Ben Beard, PhD1, Lyle Petersen, MD1, Paul Mead, MD1 (Author affiliations at end of text). |
| Lyme disease | 0.933898 |
| CDC | 0.621394 |
| clinical validation | 0.541903 |
| Human Services | 0.534763 |
| U.S. Department | 0.531113 |
| MMWR HTML versions | 0.518848 |
| Clinical Laboratory Improvement | 0.568526 |
| electronic PDF version | 0.510516 |
| specific test | 0.458119 |
| two-tier serologic testing | 0.562541 |
| Borrelia burgdorferi | 0.462133 |
| CLIA certification | 0.466068 |
| Contact GPO | 0.437057 |
| laboratory tests | 0.473895 |
| single laboratory | 0.465414 |
| original paper copy | 0.513997 |
| laboratory-developed tests | 0.473178 |
| clinical condition | 0.445859 |
| false-positive results | 0.434931 |
| novel culture method | 0.56621 |
| Western blot | 0.534338 |
| specific tests | 0.45165 |
| U.S. Government Printing | 0.522182 |
| original MMWR paper | 0.515613 |
|
| Drug Administration | 0.446318 |
| CLIA program | 0.465827 |
| new tests | 0.442278 |
| FDA-cleared immunoblot test | 0.558953 |
| clinical specimens | 0.449561 |
| testing options | 0.436013 |
| certain rare circumstances | 0.520091 |
| laboratory contamination | 0.44923 |
| laboratory-developed test | 0.574676 |
| polymerase chain reaction | 0.548687 |
| basic quality standards.* | 0.536108 |
| home brew | 0.441942 |
| complete searchable list | 0.540324 |
| routine diagnosis | 0.431652 |
| FDA clearance/approval | 0.471161 |
| diagnostic test | 0.450532 |
| two-step pre-enrichment process | 0.555446 |
| clinical validity | 0.446283 |
| Lyme disease tests | 0.675825 |
| FDA-cleared enzyme immunoassay | 0.533389 |
| FDA clearance | 0.472327 |
| Two-tier testing | 0.456072 |
| clinical usefulness | 0.469484 |
| laboratory testing | 0.450262 |
|
CLICK HERE |
| 5073 |
Centers for Disease Control and Prevention |
Html |
en |
Science Clips - Monday, December 14 2009 |
null |
| population health benefits | 0.596533 |
| colorectal cancer survival | 0.644453 |
| normal waist girth | 0.649212 |
| cardiorespiratory fitness | 0.587561 |
| CDC Knowledge | 0.631761 |
| Med Int Health. | 0.585417 |
| Action Science Clips | 0.931407 |
| public health systems | 0.605726 |
| new weekly digest | 0.587084 |
| U.S. surveillance systems | 0.588207 |
| risk factors | 0.57976 |
| kidney function | 0.577389 |
| global physical activity | 0.619551 |
| Public Health Working | 0.613078 |
| Chief Science Officer | 0.596412 |
| combined effects | 0.578704 |
| Rev Public Health. | 0.599585 |
| Clin Infect Dis. | 0.748762 |
| hematopoietic cell transplant | 0.590207 |
| hematopoietic cell | 0.598973 |
| Stephen B. Thacker | 0.665636 |
| Fulton JE | 0.717255 |
| Wingard JR | 0.597786 |
| United States | 0.637247 |
| Corso LC | 0.598558 |
|
| HIV-associated extrapulmonary tuberculosis | 0.581471 |
| television viewing | 0.577438 |
| Carlson SA | 0.604616 |
| National Public Health | 0.607727 |
| Anopheles arabiensis males | 0.580412 |
| insured patients | 0.589743 |
| U.S. reporting areas | 0.579849 |
| National Healthcare Safety | 0.58511 |
| public health | 0.731946 |
| energy intake | 0.578715 |
| Dec | 0.690815 |
| Galuska DA | 0.607932 |
| Physical activity surveillance | 0.626759 |
| public health literature | 0.605987 |
| B. Thacker CDC | 0.703449 |
| invasive pneumococcal pneumonia | 0.578976 |
| male colorectal cancer | 0.648979 |
| physical activity | 0.849569 |
| obese adults | 0.58353 |
| Phys Act Health. | 0.887805 |
| public health data | 0.610618 |
| Risk Behavior Surveillance | 0.585235 |
| older adults | 0.576826 |
| Thacker CDC Library | 0.703435 |
|
CLICK HERE |
| 8291 |
Centers for Disease Control and Prevention |
Html |
en |
Update: Severe Respiratory Illness Associated with a NovelCoronavirus - Worldwide, 2012-2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| Arabian Peninsula | 0.527205 |
| respiratory illness | 0.667123 |
| severe acute | 0.544083 |
| United States | 0.451521 |
| original MMWR paper | 0.489143 |
| U.S. Government Printing | 0.48428 |
| Human Services | 0.486871 |
| recent travel | 0.450999 |
| infection control | 0.471771 |
| MMWR website | 0.465295 |
| U.S. Department | 0.487092 |
| MMWR HTML versions | 0.485528 |
| neighboring countries | 0.451708 |
| CDC Emergency Operations | 0.520231 |
| M. Novel coronavirus | 0.601765 |
| MMWR Early Release | 0.50927 |
| electronic PDF version | 0.483782 |
| acute respiratory syndrome | 0.577795 |
| index patient | 0.585964 |
| mild illness | 0.474515 |
| novel coronavirus infection | 0.993307 |
| CDC coronavirus website | 0.797612 |
| public health risk | 0.512404 |
| local health departments | 0.568505 |
|
| underlying illness | 0.476844 |
| Respiratory specimens | 0.512542 |
| Genetic sequence analyses | 0.495958 |
| severe respiratory infection | 0.605246 |
| acute respiratory illness | 0.578343 |
| recent cluster | 0.453498 |
| World Health Organization | 0.512654 |
| adult male household | 0.489823 |
| personal protective equipment | 0.483206 |
| Contact GPO | 0.453758 |
| United Kingdom | 0.451306 |
| public health measures | 0.489954 |
| severe lower respiratory | 0.583214 |
| Brian Rha | 0.487186 |
| new virus | 0.451493 |
| severe respiratory disease | 0.644463 |
| potentially frequent updates | 0.482717 |
| original paper copy | 0.480165 |
| Respiratory Diseases | 0.503488 |
| UK Health Protection | 0.5034 |
| human infection | 0.488084 |
| human coronaviruses | 0.457977 |
| Illness onsets | 0.4877 |
|
CLICK HERE |
| 8843 |
Centers for Disease Control and Prevention |
Html |
en |
Vaccines: Healthcare Workers Need Vaccines Too - Adults - CDC |
Maintaining immunity to these diseases is an important preventive practice for HCWs. If you work directly with paitents or handle material that could spread infection, you should get appropriate vaccines to reduce the chance you will get sick and to prevent spreading diseases to your coworkers, patients, or family members. |
| VIS | 0.3212 |
| hospital volunteers | 0.414207 |
| Infection Control | 0.400438 |
| Pertussis | 0.322955 |
| one-time dose | 0.487211 |
| Vaccine Information Statements | 0.555416 |
| rubella component | 0.430413 |
| physicians | 0.319857 |
| APIC | 0.324554 |
| helpful resource materials | 0.482457 |
| prior vaccination | 0.650486 |
| emergency medical personnel | 0.506513 |
| Healthcare workers | 0.523949 |
| varicella vaccine | 0.579606 |
| family members | 0.423701 |
| (Influenza) | 0.420334 |
| influenza vaccine | 0.4926 |
| up-to-date blood test | 0.910115 |
| patients | 0.343983 |
| Pregnant HCWs | 0.397159 |
| recommended vaccines | 0.432759 |
| dose | 0.594 |
| (Chickenpox) | 0.483677 |
| exposure | 0.319627 |
|
| Td boosters | 0.41372 |
| previous dose | 0.48312 |
| healthcare institutions | 0.399867 |
| serologic evidence | 0.622173 |
| mumps | 0.381592 |
| potential risks | 0.400254 |
| doses | 0.38951 |
| N. meningitidis | 0.413258 |
| immunity | 0.387525 |
| appropriate vaccines | 0.435997 |
| laboratory technicians | 0.41309 |
| administrative staff | 0.410546 |
| combination vaccine | 0.474419 |
| pharmacists | 0.320872 |
| complete hepB vaccine | 0.583497 |
| dental professionals | 0.411547 |
| hepatitis | 0.340243 |
| Diphtheria | 0.322504 |
| series | 0.319567 |
| isolates | 0.324788 |
| worker immunization programs | 0.485258 |
| vaccine-preventable diseases | 0.429761 |
| nursing students | 0.411369 |
| measles | 0.38396 |
|
CLICK HERE |
| 10068 |
Centers for Disease Control and Prevention |
Html |
en |
Silica, Engineering Controls for Silica in Construction - Jackhammer - NIOSH Workplace Safety and Health Topic |
This NIOSH Topic Page presents information and links to other resources about Silica and Silicosis, and provides information to help workers protect themselves from occupational exposure to Silica. |
| spray angle | 0.444418 |
| dust exposures | 0.463107 |
| pneumatic jackpicks | 0.361943 |
| Lower flow rates | 0.36799 |
| ounces | 0.221669 |
| water spray device | 0.425363 |
| spray pattern | 0.348777 |
| concrete pavement | 0.30981 |
| commercially available retrofit | 0.38719 |
| water attachments | 0.300494 |
| water-spray control | 0.389213 |
| bar | 0.23342 |
| water-spray attachment | 0.313414 |
| respirable crystalline silica | 0.499977 |
| built-in water-spray units | 0.382806 |
| water sprays | 0.303112 |
| dust control | 0.528751 |
| solid-cone nozzle | 0.307518 |
| atomisation | 0.222117 |
| Construction workers | 0.312524 |
| handheld demolition | 0.288919 |
| crystalline silica dust | 0.493448 |
| hazardous dust | 0.455244 |
| soil compacting equipment | 0.367792 |
| dust controls | 0.412905 |
|
| water spray | 0.488511 |
| airborne dust | 0.463698 |
| water spray control | 0.441673 |
| RCS | 0.223105 |
| Workplace Solution | 0.296975 |
| milligrams | 0.2173 |
| jackhammer | 0.49457 |
| critical design parameters | 0.37504 |
| Engineering Controls video | 0.905447 |
| cubic meter | 0.303505 |
| E.E. Cruz Company | 0.360473 |
| Download | 0.233046 |
| South Plainfield | 0.290005 |
| In-depth survey report | 0.35853 |
| critical design parameter | 0.375542 |
| water flow rates | 0.3822 |
| NIOSH partner | 0.322022 |
| water flow rate | 0.38364 |
| right | 0.233393 |
| 80-degree spray angle | 0.443467 |
| New Jersey | 0.28859 |
| respirable dust exposure | 0.729503 |
| critical design | 0.389734 |
| jackhammers | 0.301418 |
|
CLICK HERE |
| 11116 |
Centers for Disease Control and Prevention |
Html |
en |
2008 National Report on Biochemical Indicators of Diet and Nutrition - Frequently Asked Questions |
null |
| critical nutritional data | 0.489793 |
| CDC | 0.578789 |
| CDC’s National | 0.50361 |
| Page | 0.498643 |
| nutritional status—biochemical measurements—that | 0.480431 |
| dietary supplements. | 0.500183 |
| Potential public health | 0.481184 |
| public health uses | 0.53209 |
| health outcomes | 0.474164 |
| CDC’s nutrition | 0.498285 |
| problems. Independent research | 0.519649 |
| Nutrition Examination Survey | 0.53271 |
| new biochemical indicators | 0.607821 |
| CDC publication | 0.504241 |
| National Center | 0.470777 |
| general U.S. population | 0.537987 |
| public health officials | 0.528487 |
| potential health relevance. | 0.481832 |
| CDC fact sheet | 0.490162 |
| National Health | 0.481386 |
| biochemical indicators | 0.987504 |
| Environmental Health Laboratory | 0.485056 |
| first-of-its-kind report | 0.475742 |
| human health studies | 0.478686 |
| Web site | 0.48719 |
|
| wide range | 0.470235 |
| nutritional status—biochemical measurements—other | 0.488759 |
| demographic reference information | 0.471511 |
| 95th percentile levels | 0.479176 |
| urine. Biochemical indicators | 0.629714 |
| nutrition report | 0.555628 |
| iron-status indicators | 0.532959 |
| u.s. population | 0.64923 |
| public health | 0.571881 |
| National Report | 0.480678 |
| nutritional status | 0.715754 |
| health problems. Independent | 0.531186 |
| adequate biochemical levels | 0.614049 |
| comprehensive reference information | 0.48698 |
| population reference levels | 0.488905 |
| biochemical indicator | 0.660663 |
| special population groups | 0.473385 |
| food safety | 0.475362 |
| public health efforts | 0.524104 |
| 90th percentile levels | 0.479107 |
| report | 0.679999 |
| information | 0.520938 |
| nutritional indicators | 0.52382 |
| related biochemical compounds | 0.554598 |
|
CLICK HERE |
| 13350 |
Centers for Disease Control and Prevention |
Html |
en |
Use of Serogroup B Meningococcal Vaccines in Persons Aged?10 Years at Increased Risk for Serogroup B Meningococcal Disease:Recommendations of the Advisory Committee on ImmunizationPractices, 2015 |
Please note: An erratum has been published for this article. To view the erratum, please click here. |
| United States | 0.632213 |
| meningococcal disease epidemiology | 0.668464 |
| Vaccines Work Group | 0.675167 |
| certain groups | 0.582276 |
| 10,000-fold increased risk | 0.593908 |
| Vaccine Preventable Diseases | 0.580301 |
| geometric mean titer | 0.622728 |
| serogroup B strains | 0.605565 |
| Immunization Practices | 0.601776 |
| concomitant vaccine antigens | 0.582119 |
| meningococcal conjugate vaccine | 0.656831 |
| college students | 0.578159 |
| meningococcal laboratory workers | 0.6338 |
| Practices Meningococcal Vaccines | 0.665088 |
| clinical trials | 0.771176 |
| composite hSBA response | 0.746743 |
| increased risk | 0.600454 |
| 3-dose series | 0.592511 |
| National Center | 0.581687 |
| ACIP Meningococcal Vaccines | 0.752952 |
| test strains | 0.692009 |
| 2-dose series | 0.593897 |
| lower limit | 0.578902 |
|
| vaccine efficacy estimates | 0.584616 |
| immunogenicity extension study | 0.579118 |
| MenB-FHbp | 0.597642 |
| Serogroup B Meningococcal | 0.709639 |
| subjects | 0.587884 |
| MenB vaccine | 0.628376 |
| unpublished data | 0.814859 |
| Vaccine Adverse Event | 0.592082 |
| serogroup B. | 0.58145 |
| adverse events | 0.711348 |
| immunogenicity data | 0.584196 |
| MenB vaccines | 0.802786 |
| meningococcal disease | 0.969736 |
| persons | 0.692122 |
| study investigator | 0.57989 |
| serogroup | 0.710073 |
| Novartis Vaccines | 0.578082 |
| laboratory-acquired meningococcal infection | 0.6458 |
| Respiratory Diseases | 0.578706 |
| mean titer ratio | 0.623206 |
| risk | 0.617661 |
| human papillomavirus vaccine | 0.580573 |
| Meningococcal Vaccines Work | 0.753519 |
|
CLICK HERE |
| 14443 |
Centers for Disease Control and Prevention |
Html |
en |
ADHD in Young Children |
CDC Vital Signs links science, policy, and communications with the intent of communicating a call-to-action for the public. CDC Vital Signs provides the most recent, comprehensive data on key indicators of important health topics. |
| healthcare providers | 0.492482 |
| ADHD | 0.911518 |
| CDC | 0.234353 |
| specific ways | 0.376195 |
| instances | 0.238552 |
| behavior therapy | 0.552587 |
| webinar series | 0.383589 |
| training | 0.230808 |
| potential providers | 0.359336 |
| Attention-deficit/hyperactivity disorder | 0.414491 |
| biological disorder | 0.391211 |
| effective treatment | 0.366894 |
| relationships | 0.231386 |
| Clinical guidelines | 0.373373 |
| young children | 0.847149 |
| health care professionals | 0.497063 |
| important first step | 0.380221 |
|
| therapists | 0.233375 |
| families | 0.260049 |
| psychological services | 0.368353 |
| Behavioral Health | 0.360976 |
| impulsiveness | 0.262864 |
| child’s behavior | 0.371235 |
| appropriate treatment | 0.35931 |
| key role | 0.395515 |
| effects | 0.23268 |
| attention problems | 0.399326 |
| ADHD treatment recommend | 0.701261 |
| National Council | 0.368333 |
| information | 0.229609 |
| ADHD symptoms | 0.57869 |
| ADHD medicine | 0.546865 |
| support | 0.231701 |
|
CLICK HERE |
| 15661 |
Centers for Disease Control and Prevention |
Html |
en |
Disparities in Adult Cigarette Smoking - United States, 2002-2005 and 2010-2013 | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| highest prevalence | 0.284696 |
| National Health Interview | 0.273432 |
| Puerto Ricans | 0.427906 |
| Asian Indians | 0.310491 |
| higher smoking prevalence | 0.398802 |
| whites | 0.260945 |
| current cigarette smoking§ | 0.297129 |
| respective racial/ethnic population | 0.263577 |
| tobacco | 0.287924 |
| Koreans | 0.259604 |
| current smoking | 0.271475 |
| current cigarette smoking | 0.432879 |
| wide within-group variations | 0.287963 |
| estimates | 0.273592 |
| disparities | 0.268384 |
| racial/ethnic populations/subgroups | 0.26919 |
| Health Interview Survey | 0.273464 |
| racial/ethnic populations | 0.576472 |
| significantly lower prevalence | 0.294161 |
| Asian Indian | 0.271459 |
| tobacco products | 0.275996 |
| Native Hawaiians/Pacific Islanders | 0.34099 |
| respective racial/ethnic populations | 0.268713 |
| women | 0.305708 |
| U.S. adult cigarette | 0.348773 |
|
| U.S. racial/ethnic populations | 0.272567 |
| overall prevalence | 0.424516 |
| racial/ethnic population categories | 0.302265 |
| differences | 0.310122 |
| significant changes | 0.265632 |
| adult cigarette smoking | 0.47949 |
| cigarette smoking | 0.976203 |
| men | 0.310592 |
| disaggregated racial/ethnic subgroups | 0.280963 |
| cigarette smoking prevalences | 0.40126 |
| disproportionately higher smoking | 0.389312 |
| American Indians/Alaska Natives | 0.642813 |
| evidence-based cessation services | 0.286146 |
| overall cigarette smoking | 0.3854 |
| comprehensive smoke-free policies | 0.292355 |
| Asian subgroups | 0.284824 |
| U.S. adults | 0.27122 |
| cigarette smoking prevalence | 0.827021 |
| Hispanic subgroups | 0.324753 |
| disproportionately higher prevalences | 0.260528 |
| Puerto Rican | 0.27484 |
| self-reported cigarette smoking | 0.338635 |
| highest cigarette smoking | 0.391394 |
| higher smoking prevalences | 0.300571 |
|
CLICK HERE |